glp/gip/glucagon & cagrilintide Major physiological roles of GLP-1 and GIP. Tirzepatide is acting as an...

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit

28.83

★★★★☆4.8 (126)

Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care

23.09

★★★★★4.9 (98)

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

26.03

★★★★★5.0 (157)

Effects of GLP-1 (blue arrows), glucagon (red arrows) and GIP (green

24.38

★★★★★4.7 (84)

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal

23.01

★★★★★4.9 (203)

Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports

20.11

★★★★★5.0 (176)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors

26.63

★★★★★4.8 (132)